Research ArticleArticle
Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto and Tadamitsu Kishimoto
The Journal of Rheumatology March 2014, jrheum.130690; DOI: https://doi.org/10.3899/jrheum.130690
Shumpei Yokota
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Tomoyuki Imagawa
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Masaaki Mori
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Takako Miyamae
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Syuji Takei
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Naomi Iwata
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Hiroaki Umebayashi
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Takuji Murata
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Mari Miyoshi
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Minako Tomiita
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Norihiro Nishimoto
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Tadamitsu Kishimoto
From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan. Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease. S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center. Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp. Accepted for publication December 13, 2013.
Article Information
jrheum.130690
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online March 15, 2014.
Article Versions
- You are currently viewing a Latest version of this article (March 15, 2014 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2014 The Journal of Rheumatology
Author Information
- Shumpei Yokota,
- Tomoyuki Imagawa,
- Masaaki Mori,
- Takako Miyamae,
- Syuji Takei,
- Naomi Iwata,
- Hiroaki Umebayashi,
- Takuji Murata,
- Mari Miyoshi,
- Minako Tomiita,
- Norihiro Nishimoto and
- Tadamitsu Kishimoto
- From the Department of Pediatrics, Yokohama City University School of Medicine, and Department of Pediatrics, Yokohama City University Medical Center; Yokohama; School of Health Science, Faculty of Medicine, Kagoshima University, Kagoshima; Aichi Children’s Health and Medical Center, Aichi; Miyagi Children’s Hospital, Miyagi; Department of Pediatrics, Osaka Medical College, Osaka; Kobe Children’s Hospital, Kobe; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba; Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Osaka; Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Sponsored by Chugai Pharmaceuticals. Editorial support was provided by Genentech Inc. Dr. Yokota receives a consulting fee for an advisory board from Chugai Pharmaceuticals and is a joint patent holder for tocilizumab (TCZ) for treatment of systemic juvenile idiopathic arthritis (sJIA). Dr. Miyamae is a joint patent holder for TCZ for treatment of sJIA. Dr. Umebayashi is on the speakers’ bureaus for Chugai Pharmaceuticals and Pfizer and receives travel fees from Chugai Pharmaceuticals. Dr. Kishimoto has a patent for TCZ for treatment of inflammatory disorders, including rheumatoid arthritis and Castleman disease.
S. Yokota, MD; T. Imagawa, MD; T. Miyamae, MD, Department of Pediatrics, Yokohama City University School of Medicine; S. Takei, MD, School of Health Science, Faculty of Medicine, Kagoshima University; N. Iwata, MD, Aichi Children’s Health and Medical Center; H. Umebayashi, MD, Miyagi Children’s Hospital; T. Murata, MD, Department of Pediatrics, Osaka Medical College; M. Miyoshi, MD, Kobe Children’s Hospital; M. Tomiita, MD, Department of Pediatrics, Graduate School of Medicine, Chiba University; N. Nishimoto, MD, Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University; T. Kishimoto, MD, Immunology Frontier Research Center, Osaka University; M. Mori, MD, Yokohama City University Medical Center.
Address correspondence to Prof. S. Yokota, Department of Pediatrics, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236–0004, Japan. E-mail: syokota@med.yokohama-cu.ac.jp.
Accepted for publication December 13, 2013.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto
The Journal of Rheumatology Mar 2014, jrheum.130690; DOI: 10.3899/jrheum.130690
Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan
Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto
The Journal of Rheumatology Mar 2014, jrheum.130690; DOI: 10.3899/jrheum.130690